Repligen (RGEN) 10-Q 4 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Jul. 29, 2016
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Trading Symbol	RGEN
Entity Registrant Name	REPLIGEN CORP
Entity Central Index Key	730,272
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		33,786,517

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 172,622	$ 54,092
Marketable securities	9,181	17,682
Accounts receivable, less reserve for doubtful accounts of $19 and $31, respectively	11,073	11,300
Other receivables	564	82
Inventories	23,197	17,998
Prepaid expenses and other current assets	1,304	2,098
Total current assets	217,941	103,252
Property, plant and equipment, net	13,707	13,801
Long-term marketable securities	0	1,633
Intangible assets, net	19,186	12,755
Goodwill	31,026	14,346
Restricted cash	450	450
Total assets	282,310	146,237
Current liabilities:
Accounts payable	7,688	6,724
Accrued liabilities	13,662	12,057
Total current liabilities	21,350	18,781
Convertible senior notes	93,380
Deferred tax liabilities	1,978	451
Other long-term liabilities	1,878	4,257
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $.01 par value, 5,000,000 shares authorized, no shares issued or outstanding
Common stock, $.01 par value, 80,000,000 shares authorized, 33,691,278 shares at June 30, 2016 and 32,949,353 shares at December 31, 2015 issued and outstanding	337	329
Additional paid-in capital	238,617	202,527
Accumulated other comprehensive loss	(9,184)	(8,566)
Accumulated deficit	(66,046)	(71,542)
Total stockholders' equity	163,724	122,748
Total liabilities and stockholders' equity	$ 282,310	$ 146,237

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Accounts receivable, reserve for doubtful accounts	$ 19	$ 31
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	33,691,278	32,949,353
Common stock, shares outstanding	33,691,278	32,949,353

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Product revenue	$ 29,170	$ 21,457	$ 54,265	$ 42,274
Operating expenses:
Cost of product revenue	12,644	8,586	23,713	16,659
Research and development	1,890	1,252	3,430	2,819
Selling, general and administrative	8,140	6,242	15,159	12,267
Contingent consideration - fair value adjustments	637	768	2,642	1,881
Total operating expenses	23,311	16,848	44,944	33,626
Income from operations	5,859	4,609	9,321	8,648
Investment income	76	19	137	56
Interest expense	(638)	(8)	(643)	(17)
Other income (expense)	75	(269)	(904)	(137)
Income before income taxes	5,372	4,351	7,911	8,550
Income tax provision	1,500	739	2,415	2,008
Net income	$ 3,872	$ 3,612	$ 5,496	$ 6,542
Earnings per share:
Basic	$ 0.12	$ 0.11	$ 0.16	$ 0.20
Diluted	$ 0.11	$ 0.11	$ 0.16	$ 0.19
Weighted average shares outstanding:
Basic	33,649,296	32,870,473	33,336,989	32,827,536
Diluted	34,175,127	33,670,696	33,862,311	33,581,682
Other comprehensive income:
Unrealized gain (loss) on investments		$ (5)	$ 15	$ (22)
Foreign currency translation gain (loss)	$ (2,514)	1,447	(633)	(2,402)
Comprehensive income	$ 1,358	$ 5,054	$ 4,878	$ 4,118

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net income	$ 5,496	$ 6,542
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	2,465	2,295
Non-cash interest expense	382
Stock-based compensation expense	2,059	1,687
Deferred tax expense	218	173
Loss on revaluation of contingent consideration	2,642	1,881
Gain on sale of fixed assets	(15)
Loss on disposal of assets	26	1
Changes in assets and liabilities:
Accounts receivable	892	(6,820)
Other receivables	(318)	(283)
Inventories	(5,093)	(2,380)
Prepaid expenses and other current assets	793	981
Accounts payable	511	586
Accrued liabilities	(3,239)	875
Long-term liabilities	(66)	(425)
Net cash provided by operating activities	6,753	5,113
Cash flows from investing activities:
Acquisition of Atoll GmbH, net of cash received	(8,767)
Purchases of marketable securities	(3,952)	(8,119)
Redemptions of marketable securities	14,100	10,359
Proceeds from sale of fixed assets	45
Purchases of property, plant and equipment	(1,406)	(1,737)
Net cash provided by investing activities	20	503
Cash flows from financing activities:
Proceeds from issuance of convertible senior notes, net of costs	111,323
Exercise of stock options	958	686
Payment of contingent considerations	(498)	(99)
Net cash provided by financing activities	111,783	587
Effect of exchange rate changes on cash and cash equivalents	(26)	(1,554)
Net increase in cash and cash equivalents	118,530	4,649
Cash and cash equivalents, beginning of period	54,092	35,363
Cash and cash equivalents, end of period	172,622	40,012
Supplemental disclosure of non-cash activities:
Income taxes paid	1,981	$ 1,629
Payment of contingent consideration in common stock	875
Stock tendered for acquisition of Atoll GmbH	$ 14,135

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Basis of Presentation	1. Basis of Presentation The consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company,” “Repligen” or “we”) in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by U.S. GAAP. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB, Atoll GmbH (as of April 1, 2016) and Repligen Singapore Pte. Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year. Recently Issued Accounting Pronouncements In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, “Interest – Imputation of Interest (Topic 835): Simplifying the Presentation of Debt Issuance Costs.” ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The ASU became effective for public entities for fiscal years beginning after December 15, 2015. The Company applied the amended presentation requirements in conjunction with its issuance of convertible senior notes in the second quarter of 2016. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606),” which supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, Revenue Recognition Revenue from Contracts with Customers In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory.” (“ASU 2015-11”) ASU 2015-11 requires inventory be measured at the lower of cost and net realizable value, and options that currently exist for market value be eliminated. ASU 2015-11 defines net realizable value as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective prospectively for reporting periods beginning after December 15, 2016 and interim periods within those fiscal years with early adoption permitted. The Company does not expect the adoption of ASU 2015-11 to have a material impact on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842).” (“ASU 2016-02”) ASU 2016-02 requires lessees to recognize a right-of-use asset and a lease liability for most leases. Extensive quantitative and qualitative disclosures, including significant judgments made by management, will be required to provide greater insight into the extent of revenue and expense recognized and expected to be recognized from existing contracts. The accounting applied by a lessor is largely unchanged from that applied under the current standard. The standard must be adopted using a modified retrospective transition approach and provides for certain practical expedients. The ASU is effective for public entities for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has not yet completed its assessment of the impact of the new standard on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”, which aims to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, classification of certain items on the statement of cash flows and accounting for forfeitures. The ASU is effective for public entities for fiscal years beginning after December 15, 2016, with early adoption permitted. The Company has not yet completed its assessment of the impact of the new standard on its consolidated financial statements.

Acquisition of Atoll GmbH

Acquisition of Atoll GmbH	6 Months Ended
	Jun. 30, 2016
Acquisition of Atoll GmbH	2. Acquisition of Atoll GmbH On April 1, 2016, the Company’s subsidiary Repligen Sweden AB (“Repligen Sweden”) acquired Atoll GmbH (“Atoll”) from UV-Cap GmbH & Co. KG (the “Seller”) pursuant to a Share Purchase Agreement (the “Share Purchase Agreement”), dated as of March 31, 2016 (such acquisition, the “Atoll Acquisition”), by and among Repligen Sweden, the Seller, and the Company, in its capacity as guarantor of the obligations of Repligen Sweden under the Share Purchase Agreement. The Transaction was subject to certain closing conditions that did not occur until April 1, 2016. Payment for the Transaction was denominated in Euros but is reflected here in U.S. dollars for presentation purposes. In connection with the Atoll Acquisition, the Company issued and contributed 538,700 shares of the Company’s common stock, par value of $0.01 per share valued at $14.1 million (the “Stock Consideration”) to Repligen Sweden through a transfer by the Company on behalf of Repligen Sweden to fulfill Repligen Sweden’s obligation to deliver the Stock Consideration under the Share Purchase Agreement. The issuance of the Stock Consideration will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act. The Stock Consideration was based on the fair value of Repligen stock on April 1, 2016. This acquisition strengthened Repligen’s bioprocessing business by adding a complementary extension to an existing product line while expanding its direct sales presence worldwide. The Atoll Acquisition was accounted for as a purchase of a business under ASC 805, Business Combinations. The total purchase price of the Atoll acquisition totaled $25.3 million, consisting of an upfront cash payment of $10.2 million, less $74,000 as a result of the final determination of working capital, issuance of the Share Consideration, and future potential milestone payments totaling up to $1.1 million if specific revenue growth targets are met for 2016. The $1.1 million potential contingent consideration had an initial probability weighted fair value at the time of the closing of the Transaction of approximately $952,000. Consideration Transferred The Company accounted for the Atoll Acquisition as the purchase of a business under U.S. GAAP. Under the acquisition method of accounting, the assets of Atoll were recorded as of the acquisition date, at their respective fair values, and consolidated with those of Repligen. The fair value of the net assets acquired was approximately $25.3 million. The preparation of the valuation required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable. However, actual results may differ from these estimates. The total consideration transferred follows (in thousands): Cash consideration, less $74 of working capital adjustments reflected in other receivables as of June 30, 2016 $ 10,176 Value of common stock issued 14,138 Estimated fair value of contingent consideration 952 Total consideration transferred $ 25,266 The fair value of contingent consideration was determined based upon a probability weighted analysis of expected future milestone and settlement payments to be made to the Seller. The Company could make payments of up to $1.1 million if specific revenue growth targets are met for 2016. The liability for contingent consideration is included in current liabilities on the consolidated balance sheets and will be remeasured at each reporting period until the contingency is resolved. See Note 10 - Accrued Liabilities for further details. Acquisition related costs are not included as a component of consideration transferred, but are expensed in the periods in which the costs are incurred. The Company incurred $1,119,000 in transaction costs related to the Atoll Acquisition. The transaction costs are included in selling, general and administrative expenses in the consolidated statements of operations. Fair Value of Net Assets Acquired The allocation of purchase price was based on the fair value of assets acquired and liabilities assumed as of April 1, 2016. The components and allocation of the purchase price consists of the following amounts (in thousands): Cash and cash equivalents $ 1,409 Accounts receivable 697 Inventory 155 Other current assets 169 Fixed assets, net 114 Customer relationships 5,318 Developed technology 2,175 Non-competition agreements 57 Trademark and trade name 11 Deferred tax assets 903 Accounts payable and other liabilities assumed (599 ) Deferred tax liabilities (2,245 ) Goodwill 17,102 Net assets acquired $ 25,266 Of the consideration paid, $5.3 million represents the fair value of customer relationships that will be amortized over the determined useful life of 16 years and $2.2 million represents the fair value of developed technology that will be amortized over a determined useful life of 14 years. $57,000 represents the fair value of non-competition agreements, and $11,000 represents the fair value of trademarks and trade names that will be amortized over a determined useful life of 2 years. The aforementioned intangible assets will be amortized on a straight-line basis. The assessment of fair value is preliminary and is based on information that was available to management at the time the condensed consolidated financial statements were prepared. The Company is finalizing its valuation of the assets acquired and liabilities assumed, and accordingly, such amounts may be subject to change.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2016
Revenue Recognition	3. Revenue Recognition Product Sales The Company’s revenue recognition policy is to recognize revenues from product sales and services in accordance with ASC 605, Revenue Recognition The Company’s product revenues are from the sale of bioprocessing products, equipment devices, and related consumables used with these equipment devices to customers in the life science and biopharmaceutical industries. On product sales to end customers, revenue is recognized, net of discounts, when both the title and risk of loss have transferred to the customer, as determined by the shipping terms provided there are no uncertainties regarding acceptance, and all obligations have been completed. Generally, our product arrangements for equipment sales are multiple element arrangements, and may include services, such as installation and training, and multiple products, such as consumables and spare parts. In accordance with ASC 605-25, based on terms and conditions of the product arrangements, the Company believes that these services and undelivered products can be accounted for separately from the delivered product element, as the delivered products have value to our customers on a standalone basis. Accordingly, revenue for services not yet performed at the time of product shipment are deferred and recognized as such services are performed. The relative selling price of any undelivered products is also deferred at the time of shipment and recognized as revenue when these products are delivered. For product sales to distributors, the Company recognizes revenue for both equipment and consumables upon delivery to the distributor unless direct shipment to the end user is requested. In this case, revenue is recognized upon delivery to the end user’s location. In general, distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. Sales to distributors are not contingent upon resale of the product. At the time of sale, the Company also evaluates the need to accrue for warranty and sales returns. The supply agreements the Company has with its customers and the related purchase orders identify the terms and conditions of each sale and the price of the goods ordered. Due to the nature of the sales arrangements, inventory produced for sale is tested for quality specifications prior to shipment. Since the product is manufactured to order and in compliance with required specifications prior to shipment, the likelihood of sales return, warranty or other issues is largely diminished. Furthermore, there is no customer right of return in our sales agreements. Sales returns and warranty issues are infrequent and have not had a material impact on the Company’s financial statements historically. Shipping and handling fees are recorded as a component of product revenue, with the associated costs recorded as a component of cost of product revenue. Therapeutics Licensing Agreements Activities under licensing agreements are evaluated in accordance with ASC 605-25 to determine if they represent a multiple element revenue arrangement. The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting. The Company accounts for those components as separate units of accounting if the following two criteria are met: • The delivered item or items have value to the customer on a stand-alone basis. • If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company’s control. Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables. If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative selling price. Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. Future milestone payments, if any, under a license agreement will be recognized under the provisions of ASC 605-28, which the Company adopted on January 1, 2011. The Company has elected to recognize a payment that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is substantive if: • It can only be achieved based in whole or in part on either the Company’s performance or the occurrence of a specific outcome resulting from the Company’s performance; • There is substantive uncertainty at the date an arrangement is entered into that the event will be achieved; and • It would result in additional payments being due to the entity. The commercial milestone payments and royalty payments received under license agreements, if any, will be recognized as revenue when they are earned. Sale of Intellectual Property to BioMarin In January 2014, the Company entered into an asset purchase agreement (the “BioMarin Asset Purchase Agreement”) with BioMarin Pharmaceutical Inc. (“BioMarin”) to sell Repligen’s histone deacetylase inhibitor (HDACi) portfolio. Pursuant to the terms of the BioMarin Asset Purchase Agreement, the Company received $2 million from BioMarin as an upfront payment on January 30, 2014 and a $125,675 payment on September 3, 2014 upon completion of the Technology Transfer. The Company is entitled to receive up to $160 million in potential future milestone payments for the development, regulatory approval and commercial sale of portfolio compounds included in the agreement. These potential milestone payments are approximately 37% related to clinical development and 63% related to initial commercial sales in specific geographies. In addition, Repligen is eligible to receive royalties on sales of therapeutic products originating from the HDACi portfolio. The royalty rates are tiered and begin in the mid-single-digits for the first HDACi portfolio product and for the first non-HDACi portfolio product with lesser amounts for any backup products developed under the BioMarin Asset Purchase Agreement. Repligen’s receipt of these royalties is subject to customary offsets and deductions. There are no refund provisions in this agreement. Any milestones earned upon specified clinical development or commercial sales events or future royalty payments, under the BioMarin Asset Purchase Agreement will be recognized as revenue when they are earned. Activities under this agreement were evaluated in accordance with ASC 605-25 to determine if they represented a multiple element revenue arrangement. The Company identified the following deliverables in the BioMarin Asset Purchase Agreement: • The assignment by Repligen to BioMarin of the Repligen Technology (“Repligen Know-How” and “Repligen Patents”) and the Scripps Agreement (the “Transferred Assets”); • The transfer of certain notebooks, data, documents, biological materials (if any) and other such documents in our possession that might be useful to further development of the program (the “Technology Transfer”). Two criteria must be met in order for a deliverable to be considered a separate unit of accounting. The first criterion requires that the delivered item or items have value to the customer on a stand-alone basis. The second criterion, which relates to evaluating a general right of return, is not applicable because such a provision does not exist in the BioMarin Asset Purchase Agreement. The deliverables outlined above were deemed to have stand-alone value and to meet the criteria to be accounted for as separate units of accounting. Factors considered in this determination included, among other things, BioMarin’s right under the agreement to assign the Transferred Assets, whether any other vendors sell the items separately and if BioMarin could use the delivered item for its intended purpose without the receipt of the remaining deliverables. If multiple deliverables included in an arrangement are separable into different units of accounting, the multiple-element arrangements guidance addresses how to allocate the arrangement consideration to those units of accounting. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative selling price. The Company identified the arrangement consideration to allocate among the units of accounting as the $2.0 million non-refundable up-front payment and the $125,675 payment to be received upon completion of the Technology Transfer. The Company excluded the potential milestone payments provided for in the BioMarin Asset Purchase Agreement from the arrangement consideration as they were not considered fixed or determinable at the time the BioMarin Asset Purchase Agreement was signed. Because Repligen had not sold these items on a standalone basis previously, Repligen had no vendor-specific objective evidence of selling price. Furthermore, Repligen did not have detailed third-party evidence of selling price, and as a result we used our best estimate of selling price for each item. In determining these prices, Repligen considered what Repligen would be willing to sell the items for on a standalone basis, what the market would bear for such items and what another party might charge for these items. The up-front arrangement consideration allocated to the Transferred Assets was recognized upon execution of the BioMarin Asset Purchase Agreement as the risks and rewards associated with the Transferred Assets transferred at that time. The Company used a discounted cash flow analysis to determine the value of the Transferred Assets. Key assumptions in the analysis included: the estimated market size for a compound targeted at Friedreich’s Ataxia, the estimated remaining costs of development and time to commercialization, and the probability of successfully developing and commercializing the program. Based on this analysis, the Company allocated $2,115,000 to the value of the Transferred Assets. However, as the recognized revenue is limited to the non-contingent consideration received, the Company recognized $2,000,000, the amount of the up-front payment, as revenue in the three months ended March 31, 2014. In addition to the $2.1 million up-front payment, the Company is also eligible to receive up to $160 million in potential milestone payments from BioMarin comprised of: • Up to $60 million related to the achievement of specified clinical and regulatory milestone events; and • Up to $100 million related to the achievement of specified commercial sales events, specifically the first commercial sale in specific territories. The Company evaluated the potential milestones in accordance with ASC 605-28, which allows an entity to make an accounting policy election to recognize a payment that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. This evaluation included an assessment of the risks that must be overcome to achieve the respective milestone as well as whether the achievement of the milestone was due in part to our initial clinical work, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met. The Company believes that the $60 million of specified clinical and regulatory milestone payments are substantive. Therefore, any such milestones achieved will be recognized as revenue when earned. Any milestones achieved upon specified commercial sales events or future royalty payments are considered contingent revenue under the BioMarin Asset Purchase Agreement, and will be recognized as revenue when they are earned as there are no undelivered elements remaining and no continuing performance obligations under the arrangement.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
	Jun. 30, 2016
Accumulated Other Comprehensive Income	4. Accumulated Other Comprehensive Income The following table summarizes the changes in accumulated other comprehensive income by component (in thousands): (In thousands) Unrealized gain Foreign currency Total Balance at December 31, 2015 $ (11 ) $ (8,555 ) $ (8,566 ) Other comprehensive income 15 (633 ) (618 ) Balance at June 30, 2016 $ 4 $ (9,188 ) $ (9,184 )

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2016
Earnings Per Share	5. Earnings Per Share The Company reports earnings per share in accordance with Accounting Standards Codification Topic 260, “Earnings Per Share,” which establishes standards for computing and presenting earnings per share. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares and dilutive common share equivalents then outstanding. Potential common share equivalents consist of restricted stock awards and the incremental common shares issuable upon the exercise of stock options. Under the treasury stock method, unexercised “in-the-money” stock options and warrants are assumed to be exercised at the beginning of the period or at issuance, if later. The assumed proceeds are then used to purchase common shares at the average market price during the period. Share-based payment awards that entitle their holders to receive non-forfeitable dividends before vesting are considered participating securities and are considered in the calculation of basic and diluted earnings per share. There were no such participating securities outstanding during the three-month periods ended June 30, 2016 and 2015. Basic and diluted weighted average shares outstanding were as follows: Three months ended Six months ended 2016 2015 2016 2015 Weighted average common shares 33,649,296 32,870,473 33,336,989 32,827,536 Dilutive common stock options 525,831 800,223 525,322 754,146 Weighted average common shares, assuming dilution 34,175,127 33,670,696 33,862,311 33,581,682 At June 30, 2016, there were outstanding options to purchase 1,315,739 shares of the Company’s common stock at a weighted average exercise price of $11.70 per share. For the three- and six-month periods ended June 30, 2016, 359,828 and 417,279 options to purchase shares of the Company’s common stock, respectively, were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares, and were therefore anti-dilutive. The Company has excluded the effects of its convertible senior notes issued in May 2016 on earnings per share, as it is the Company’s intent to settle these notes in cash. At June 30, 2015, there were outstanding options to purchase 1,265,486 shares of the Company’s common stock at a weighted average exercise price of $9.68 per share. For the three- and six-month periods ended June 30, 2015, 126,541 and 150,041 options to purchase shares of the Company’s common stock, respectively, were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares, and were therefore anti-dilutive.

Cash, Cash Equivalents and Mark

Cash, Cash Equivalents and Marketable Securities	6 Months Ended
	Jun. 30, 2016
Cash, Cash Equivalents and Marketable Securities	6. Cash, Cash Equivalents and Marketable Securities At June 30, 2016, the Company’s investments included money market funds and short-term marketable securities. At December 31, 2015, the Company’s investments included money market funds, short-term and long-term marketable securities. These marketable securities are classified as available-for-sale. Marketable securities are investments with original maturities of greater than 90 days. Long-term marketable securities are securities with maturities of greater than one year. The average remaining contractual maturity of marketable securities at June 30, 2016 is approximately 3.53 months. Management reviewed the Company’s investments as of June 30, 2016 and December 31, 2015 and concluded that there are no securities with other than temporary impairments in the investment portfolio. The Company does not intend to sell any investments in an unrealized loss position, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases. Investments in marketable securities consisted of the following at June 30, 2016 (in thousands): June 30, 2016 Amortized Gross Gross Fair Value Marketable securities: U.S. Government and agency securities $ 3,927 $ 2 $ — $ 3,929 Corporate and other debt securities 5,250 2 — 5,252 Total $ 9,177 $ 4 $ — $ 9,181 There were no long-term marketable securities as of June 30, 2016. At June 30, 2016, the Company’s investments included three securities in unrealized loss positions with a total unrealized loss of less than $1,000 and a total fair market value of approximately $1,302,000. All investments with gross unrealized losses have been in unrealized loss positions for less than 12 months. The unrealized losses were caused primarily by current economic and market conditions. There was no change in the credit risk of the securities. There were no realized gains or losses on the investments for the six months ended June 30, 2016 or the six months ended June 30, 2015. Investments in marketable securities consisted of the following at December 31, 2015 (in thousands): December 31, 2015 Amortized Gross Gross Fair Value Marketable securities: U.S. Government and agency securities $ 7,029 $ — $ (6 ) $ 7,023 Corporate and other debt securities 10,659 7 (7 ) 10,659 17,688 7 (13 ) 17,682 Long-term marketable securities: U.S. Government and agency securities 838 — (2 ) 836 Corporate and other debt securities 800 — (3 ) 797 1,638 — (5 ) 1,633 Total $ 19,326 $ 7 $ (18 ) $ 19,315 The contractual maturities of all money market funds and marketable securities are less than one year as of June 30, 2016.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2016
Inventories	7. Inventories Inventories relate to the Company’s bioprocessing business. The Company values inventory at cost or, if lower, market value, using the first-in, first-out method. The Company reviews its inventories at least quarterly and records a provision for excess and obsolete inventory based on its estimates of expected sales volume, production capacity and expiration dates of raw materials, work-in-process and finished products. Expected sales volumes are determined based on supply forecasts provided by key customers for the next 3 to 12 months. The Company writes down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements to cost of product revenue. Manufacturing of bioprocessing finished goods is done to order and tested for quality specifications prior to shipment. Reserves for excess and obsolete inventory were approximately $343,000 at June 30, 2016 and December 31, 2015. A change in the estimated timing or amount of demand for the Company’s products could result in additional provisions for excess inventory quantities on hand. Any significant unanticipated changes in demand or unexpected quality failures could have a significant impact on the value of inventory and reported operating results. During all periods presented in the accompanying financial statements, there have been no material adjustments related to a revised estimate of inventory valuations. Work-in-process and finished products inventories consist of material, labor, outside processing costs and manufacturing overhead. Inventories consist of the following (in thousands): June 30, December 31, Raw Materials $ 14,895 $ 10,671 Work-in-process 2,091 1,586 Finished products 6,211 5,741 Total $ 23,197 $ 17,998

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment	8. Property, Plant and Equipment Property, plant and equipment consist of the following (in thousands): June 30, 2016 December 31, 2015 Leasehold improvements $ 13,557 $ 13,306 Equipment 14,682 13,758 Furniture and fixtures 3,080 2,808 Construction in progress 621 425 Total property, plant and equipment 31,940 30,297 Less: accumulated depreciation (18,233 ) (16,496 ) Property, plant and equipment, net $ 13,707 $ 13,801 Depreciation expense totaled approximately $1,535,000 and $1,494,000 for the six-month periods ended June 30, 2016 and 2015, respectively.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2016
Intangible Assets	9. Intangible Assets Intangible assets, except for the Refine Technology, LLC tradename and in-process research and development, are amortized over their useful lives using the straight-line method, as applicable, and the amortization expense is recorded within selling, general and administrative expense in the Company’s statements of comprehensive income (loss). The Refine Technology, LLC tradename and in-process research and development are not amortized. The Company reviews its indefinite-lived intangible assets not subject to amortization to determine if adverse conditions exist or a change in circumstances exists that would indicate an impairment. Intangible assets and their related useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. More frequent impairment assessments are conducted if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for our products or changes in the size of the market for our products. An impairment results if the carrying value of the asset exceeds the estimated fair value of the asset. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. The Company continues to believe that its intangible assets are recoverable at June 30, 2016. Intangible assets consisted of the following at June 30, 2016 (in thousands): Gross Carrying Accumulated Weighted Technology – developed $ 5,413 $ (1,208 ) 13 In process research and development 1,600 — — Patents 240 (192 ) 8 Customer relationships 16,959 (4,385 ) 11 Trademark 700 — — Other intangibles 67 (8 ) 2 Total intangible assets $ 24,979 $ (5,793 ) 12 Intangible assets consisted of the following at December 31, 2015 (in thousands): Gross Carrying Accumulated Weighted Technology – developed $ 3,295 $ (782 ) 12 In process research and development 1,600 — — Patents 240 (177 ) 8 Customer relationships 11,805 (3,926 ) 9 Trademark 700 — — Total intangible assets $ 17,640 $ (4,885 ) 10 Amortization expense for amortized intangible assets was approximately $932,000 and $801,000 for the six months ended June 30, 2016 and 2015, respectively. As of June 30, 2016, the Company expects to record amortization expense as follows (in thousands): Years Ending Amortization Expense December 31, 2016 (six months remaining) $ 1,120 December 31, 2017 2,241 December 31, 2018 2,052 December 31, 2019 2,028 December 31, 2020 1,683

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2016
Accrued Liabilities	10. Accrued Liabilities Accrued liabilities consist of the following (in thousands): June 30, 2016 December 31, 2015 Employee compensation $ 3,800 $ 4,680 Accrued interest payable 251 — Accrued purchases 718 604 Taxes 457 166 Current portion of contingent consideration 5,878 4,480 Professional fees 441 269 Unearned revenue 202 258 Other accrued expenses 1,915 1,600 Total $ 13,662 $ 12,05

Long Term Debt

Long Term Debt	6 Months Ended
	Jun. 30, 2016
Long Term Debt	11. Long Term Debt The carrying value of the Company’s convertible senior notes is as follows (in thousands): June 30, 2016 December 31, 2015 2.125% Convertible Senior Notes due 2021: Principal amount $ 115,000 $ — Unamortized debt discount (18,387 ) — Unamortized debt issuance costs (3,233 ) — Total convertible senior notes $ 93,380 $ — On May 24, 2016, the Company issued $115 million aggregate principal amount of its 2.125% Convertible Senior Notes due 2021 (the “Notes”). The net proceeds from the sale of the Notes, after deducting the underwriting discounts and commissions and other related offering expenses, were approximately $111.3 million. The Notes bear interest at the rate of 2.125% per annum, payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2016. The Notes will mature on June 1, 2021, unless earlier repurchased, redeemed or converted in accordance with their terms. Prior to March 1, 2021, the Notes will be convertible at the option of holders of the Notes only upon satisfaction of certain conditions and during certain periods, and thereafter, the notes will be convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Upon conversion, holders of the Notes will receive shares of the Company’s common stock, cash or a combination thereof, at the Company’s election. It is the Company’s current intent and policy to settle all conversions through combination settlement, which involves satisfying the principal amount outstanding with cash and any note conversion value over the principal amount in shares of the Company’s common stock. The conversion rate for the Notes will initially be 31.1813 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $32.07 per common share, and is subject to adjustment under the terms of the Notes. Holders of the Notes may require the Company to repurchase their Notes upon the occurrence of a fundamental change prior to maturity for cash at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased plus accrued and unpaid interest, if any, to, but excluding, the repurchase date. The Company will not have the right to redeem the Notes prior to June 5, 2019, but may redeem the Notes, at its option, in whole or in part, on any business day on or after June 5, 2019 and prior to the maturity date if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides written notice of redemption. The redemption price will be equal to 100% of the principal amount of the principal amount of Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. The Notes contain customary terms and events of default. If an event of default (other than certain events of bankruptcy, insolvency or reorganization involving the Company) occurs and is continuing, the holders of at least 25% in aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and any accrued and unpaid interest on, all of the Notes to be due and payable. Upon the occurrence of certain events of bankruptcy, insolvency or reorganization involving the Company, 100% of the principal of and accrued and unpaid interest, if any, on all of the Notes will become due and payable automatically. Notwithstanding the foregoing, the Notes provide that, to the extent the Company elects and for up to 270 days, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants consist exclusively of the right to receive additional interest on the Notes. The Company is not aware of any events of default, current events or market conditions that would allow holders to call or convert the Notes as of June 30, 2016. The cash conversion feature of the Notes required bifurcation from the Notes and was initially accounted for as an equity instrument classified to stockholders’ equity, as the conversion feature was determined to be clearly and closely related to the Company’s stock. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in the same industry and asset base and with similar maturity, the Company estimated the implied interest rate, assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, including market interest rates, credit standing, and yield curves, all of which are defined as Level 2 observable inputs. The estimated implied interest rate was applied to the Notes, which resulted in a fair value of the liability component of $96,289,000 upon issuance, calculated as the present value of implied future payments based on the $115 million aggregate principal amount. The equity component of the Notes was recognized as a debt discount, recorded in additional paid-in capital, and represents the difference between the aggregate principal of the Notes and the fair value of the Notes without conversion option on their issuance date. The debt discount is amortized to interest expense using the effective interest method over five years, or the life of the Notes. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. Interest expense recognized on the Notes during the three month period ended June 30, 2016 includes $251,000, $324,000 and $57,000 for the contractual coupon interest, the accretion of the debt discount and the amortization of the debt issuance costs, respectively. The effective interest rate on the Notes is 6.6%, which includes the interest on the Notes, amortization of the debt discount and debt issuance costs. As of June 30, 2016, the carrying value of the Notes was approximately $93.4 million and the fair value of the principal was approximately $124.3 million.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2016
Stock-Based Compensation	12. Stock-Based Compensation For the three months ended June 30, 2016 and 2015, the Company recorded stock-based compensation expense of approximately $1,137,000 and $985,000, respectively, for share-based awards granted under the Second Amended and Restated 2001 Repligen Corporation Stock Plan (the “2001 Plan”) and the Repligen Corporation Amended and Restated 2012 Stock Option and Incentive Plan (the “2012 Plan,” and collectively with the 2001 Plan and the 1992 Repligen Corporation Stock Option Plan, the “Plans”). The Company recorded stock-based compensation expense of approximately $2,059,000 and $1,687,000 for the six-month periods ended June 30, 2016 and 2015, respectively, for share-based awards granted under the Plans. The following table presents stock-based compensation expense included in the Company’s consolidated statements of comprehensive income (in thousands): Three months ended Six months ended 2016 2015 2016 2015 Cost of product revenue $ 84 $ 63 $ 144 $ 106 Research and development 105 90 185 159 Selling, general and administrative 948 832 1,730 1,422 Total $ 1,137 $ 985 $ 2,059 $ 1,687 The 2012 Plan allows for the granting of incentive and nonqualified options to purchase shares of common stock, restricted stock and other equity awards. Incentive options granted to employees under the Plans generally vest over a three to five-year period, with 20%-33% vesting on the first anniversary of the date of grant and the remainder vesting in equal yearly installments thereafter. Nonqualified options issued to non-employee directors under the Plans generally vest over one year. Options granted under the Plans have a maximum term of ten years from the date of grant and generally, the exercise price of the stock options equals the fair market value of the Company’s common stock on the date of grant. At June 30, 2016, options to purchase 1,315,739 shares were outstanding under the Plans. At June 30, 2016, 1,976,534 shares were available for future grant under the 2012 Plan. The Company uses the Black-Scholes option pricing model to calculate the fair value of stock option awards on the grant date, and the Company uses the value of the common stock as of the grant date to value restricted stock units. The Company measures stock-based compensation cost at the grant date based on the estimated fair value of the award, and recognizes awards with service based vesting as expense over the employee’s requisite service period on a straight-line basis. The Company records the expense for share-based awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates whether the achievement of a performance-based milestone is probable as of the reporting date. The Company has no awards that are performance-based or subject to market conditions. The Company recognizes stock-based compensation expense for options that are ultimately expected to vest, and accordingly, such compensation expense has been adjusted for estimated forfeitures. Information regarding option activity for the six months ended June 30, 2016 under the Plans is summarized below: Options Weighted- Weighted- (in thousands) Aggregate Options outstanding at January 1, 2016 1,240,935 $ 10.44 Granted 331,203 12.40 Exercised (170,919 ) 5.89 Forfeited/Cancelled (85,480 ) 7.69 Options outstanding at June 30, 2016 1,315,739 $ 11.70 7.33 $ 21,147 Options exercisable at June 30, 2016 514,898 $ 9.49 5.17 $ 9,402 Vested and expected to vest at June 30, 2016 (1) 1,223,223 $ 11.88 7.26 $ 19,473 (1) This represents the number of vested options as of June 30, 2016 plus the number of unvested options expected to vest as of June 30, 2016 based on the unvested outstanding options at June 30, 2016 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees. The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on June 30, 2016 of $27.36 and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on June 30, 2016. The weighted average grant date fair value of options granted during the six months ended June 30, 2016 and 2015 was $20.11 and $21.83, respectively. The total fair value of stock options that vested during the six months ended June 30, 2016 and 2015 was approximately $2,396,000 and $1,522,000, respectively. As of June 30, 2016, there was approximately $9,613,000 of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 2.91 years. The Company expects 708,325 unvested options to vest over the next five years.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2016
Income Taxes	13. Income Taxes The Company’s effective tax rate for the three and six months ended June 30, 2016 was 27.9% and 30.5%, respectively, compared to 17.0% and 23.5%, respectively, for the corresponding periods in the prior year. For the current three and six month periods, the effective tax rate was lower than the U.S. statutory tax rate of 34% primarily due to increased foreign profits at lower tax rates, offset by unbenefited domestic losses. For the three and six months ended June 30, 2015, the effective tax rate differed from the U.S. statutory rate of 34% primarily due to the lower statutory tax rate in Sweden and a reserve reversal attributable to a correction of an income tax audit accrual. As of December 31, 2015, the Company has U.S. net operating loss carryforwards of approximately $46,984,000 and U.S. business tax credit carryforwards of approximately $1,920,000 available to reduce future federal income taxes, if any. The net operating loss and business tax credits carryforwards will continue to expire at various dates through December 2035. Net operating loss carryforwards and available tax credits are subject to review and possible adjustment by the Internal Revenue Service and may be limited in the event of certain changes in the ownership interest of significant stockholders. As of December 31, 2015, the Company concluded that realization of deferred tax assets in the United States beyond December 31, 2015 is not more likely than not, and as such, the Company maintained a valuation allowance against the majority of its remaining deferred tax assets. As of June 30, 2016, the Company concluded that realization of deferred tax assets beyond June 30, 2016 is not more likely than not, and as such, the Company maintained a valuation allowance against the majority of its remaining U.S. deferred tax assets. As a result of the Company’s acquisition of Atoll GmbH on April 1, 2016, the Company acquired intangible assets of approximately €6,640,000. Because the amortization of these intangible assets is not deductible under German tax law, the Company recorded deferred tax liabilities of approximately €1,972,000 (approximately $2,190,000) as of June 30, 2016. Additionally, the Company was able to retain net operating losses of approximately €2,669,000. Accordingly, the Company recorded deferred tax assets of approximately €793,000 (approximately $880,000) as of June 30, 2016. The fiscal years ended December 31, 2012, 2013, 2014 and 2015 are subject to examination by U.S. federal, state and Sweden taxing authorities.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2016
Fair Value Measurement	14. Fair Value Measurement In determining the fair value of its assets and liabilities, the Company uses various valuation approaches. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access Level 2 – Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. The Company’s fixed income investments are comprised of obligations of U.S. government agencies and corporate marketable securities. These investments have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. At least annually, the Company validates the prices provided by third party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active. The Company did not adjust or override any fair value measurements provided by the pricing services as of June 30, 2016. The following fair value hierarchy table presents information about each major category of the Company’s assets measured at fair value on a recurring basis as of June 30, 2016 (in thousands): Fair value measurement at reporting date using: Quoted prices in Significant Significant Total Assets: Money market funds $ 131,939 $ — $ — $ 131,939 U.S. Government and agency securities 3,629 300 — 3,929 Corporate and other debt securities — 5,252 — 5,252 Total $ 135,568 $ 5,552 $ — $ 141,120 Liabilities: Contingent consideration – short-term $ — $ — $ 5,878 $ 5,878 Convertible senior notes — 124,295 — 124,295 Total $ — $ 124,295 $ 5,878 $ 130,173 The Company has no other assets or liabilities for which fair value measurement is either required or has been elected to be applied. The liabilities for contingent consideration are recorded in connection with the BioFlash Partners, LLC (“BioFlash”), Refine Technology, LLC (“Refine”) and Atoll business combinations. The contingent consideration related to BioFlash is valued using management’s estimates of royalties to be paid to the former shareholders of BioFlash based on sales of the acquired assets. The contingent consideration related to Refine is valued using management’s estimates of expected future milestone payments based on forecasted sales and a portion of any receipts that might be received in connection with the resolution, withdrawal or settlement of certain patent disputes with a third party to be paid to Refine. The contingent consideration related to Atoll is valued using management’s estimates of expected future milestone payments based on forecasted sales. These valuations are Level 3 valuations, as the primary inputs are unobservable. Changes in the fair value of contingent consideration in the six-month period ended June 30, 2016 are primarily attributable to an increase to the expected 2016 Refine milestone payment of $2,629,000, a $4,350,000 milestone payment to Refine and a $130,000 minimum royalty payment made to BioFlash, which were previously accrued. Additionally, the Company recorded contingent consideration of €836,000 (approximately $928,000) related to the Atoll acquisition. The following table provides a rollforward of the fair value of contingent consideration (in thousands): Balance at December 31, 2015 $ 6,788 Additions 928 Payments (4,480 ) Changes in fair value 2,642 Balance at June 30, 2016 $ 5,878 The following tables provide quantitative information associated with the fair value measurement of the Company’s contingent consideration related to Refine using Level 3 inputs (in thousands): Contingent Consideration Refine Fair value as of June 30, 2016 $4,648 Valuation technique Probability-adjusted Remaining period in which milestones can be achieved 2016 Fixed Earn-out Maximum Accrued 2016 4,250 1,300 4,648 The significant unobservable inputs used in the fair value measurement of Refine’s contingent consideration are the probabilities of successful achievement of 2016 sales milestones. During the first six months of 2016, the estimated fair value of the 2016 contingent payment was increased by $2,629,000 to $4,648,000 based on revised sales forecasts. Increases or decreases in the Company’s projected sales during 2016 may result in a significantly higher or lower fair value measurement, respectively, and could result in a reversal of the current accrual. The following tables provide quantitative information associated with the fair value measurement of the Company’s contingent consideration related to Atoll using Level 3 inputs (in thousands): Contingent Consideration Atoll Fair value as of June 30, 2016 $928 Valuation technique Probability-weighted Remaining period in which milestones can be achieved 2016 The significant unobservable inputs used in the fair value measurement of Atoll’s contingent consideration are the probabilities of successful achievement of 2016 sales milestones. The initial valuation of contingent consideration upon the acquisition of Atoll in April 2016 resulted in a fair value of €836,000 (approximately $928,000). Increases or decreases in the Company’s projected sales during 2016 may result in a significantly higher or lower fair value measurement, respectively, and could result in a reversal of the current accrual. In May 2016, the Company issued $115 million aggregate principal amount of 2.125% convertible senior notes due June 1, 2021 (the “Notes”). Interest is payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2016. As of June 30, 2016, the carrying value of the Notes was $93.3 million, net of unamortized discount, and the fair value of the Notes was approximately $124.3 million. The Notes are discussed in more detail in Note 11, “Long Term Debt . There were no remeasurements to fair value during the three months ended June 30, 2016 of financial assets and liabilities that are not measured at fair value on a recurring basis.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies	15. Commitments and Contingencies Future minimum rental commitments under the Company’s leases as of June 30, 2016 are as follows (in thousands): Minimum Rental 2016 $ 2,031 2017 1,434 2018 1,434 2019 1,387 2020 1,371 Thereafter 2,700

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2016
Segment Reporting	16. Segment Reporting The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one operating segment. As a result, the financial information disclosed herein represents all of the material financial information related to the Company’s principal operating segment. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three months ended Six months ended 2016 2015 2016 2015 United States 45 % 21 % 37 % 25 % Sweden 29 % 51 % 31 % 44 % United Kingdom 6 % 17 % 10 % 18 % Other 20 % 11 % 22 % 13 % Total 100 % 100 % 100 % 100 % Revenue from significant customers as a percentage of the Company’s total revenue is as follows: Three months ended Six months ended 2016 2015 2016 2015 GE Healthcare 28 % 51 % 31 % 44 % MilliporeSigma 30 % 25 % 30 % 31 % Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable are as follows: June 30, December 31, GE Healthcare 49 % 13 % MilliporeSigma 13 % 32 % Bioprocessing Customer C 3 % 21 %

Revenue Recognition (Policies)

Revenue Recognition (Policies)	6 Months Ended
	Jun. 30, 2016
Revenue Recognition	Revenue Recognition Product Sales The Company’s revenue recognition policy is to recognize revenues from product sales and services in accordance with ASC 605, Revenue Recognition The Company’s product revenues are from the sale of bioprocessing products, equipment devices, and related consumables used with these equipment devices to customers in the life science and biopharmaceutical industries. On product sales to end customers, revenue is recognized, net of discounts, when both the title and risk of loss have transferred to the customer, as determined by the shipping terms provided there are no uncertainties regarding acceptance, and all obligations have been completed. Generally, our product arrangements for equipment sales are multiple element arrangements, and may include services, such as installation and training, and multiple products, such as consumables and spare parts. In accordance with ASC 605-25, based on terms and conditions of the product arrangements, the Company believes that these services and undelivered products can be accounted for separately from the delivered product element, as the delivered products have value to our customers on a standalone basis. Accordingly, revenue for services not yet performed at the time of product shipment are deferred and recognized as such services are performed. The relative selling price of any undelivered products is also deferred at the time of shipment and recognized as revenue when these products are delivered. For product sales to distributors, the Company recognizes revenue for both equipment and consumables upon delivery to the distributor unless direct shipment to the end user is requested. In this case, revenue is recognized upon delivery to the end user’s location. In general, distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. Sales to distributors are not contingent upon resale of the product. At the time of sale, the Company also evaluates the need to accrue for warranty and sales returns. The supply agreements the Company has with its customers and the related purchase orders identify the terms and conditions of each sale and the price of the goods ordered. Due to the nature of the sales arrangements, inventory produced for sale is tested for quality specifications prior to shipment. Since the product is manufactured to order and in compliance with required specifications prior to shipment, the likelihood of sales return, warranty or other issues is largely diminished. Furthermore, there is no customer right of return in our sales agreements. Sales returns and warranty issues are infrequent and have not had a material impact on the Company’s financial statements historically. Shipping and handling fees are recorded as a component of product revenue, with the associated costs recorded as a component of cost of product revenue. Therapeutics Licensing Agreements Activities under licensing agreements are evaluated in accordance with ASC 605-25 to determine if they represent a multiple element revenue arrangement. The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting. The Company accounts for those components as separate units of accounting if the following two criteria are met: • The delivered item or items have value to the customer on a stand-alone basis. • If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company’s control. Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables. If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative selling price. Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met. Future milestone payments, if any, under a license agreement will be recognized under the provisions of ASC 605-28, which the Company adopted on January 1, 2011. The Company has elected to recognize a payment that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is substantive if: • It can only be achieved based in whole or in part on either the Company’s performance or the occurrence of a specific outcome resulting from the Company’s performance; • There is substantive uncertainty at the date an arrangement is entered into that the event will be achieved; and • It would result in additional payments being due to the entity. The commercial milestone payments and royalty payments received under license agreements, if any, will be recognized as revenue when they are earned.
Fair Value Measurement	In determining the fair value of its assets and liabilities, the Company uses various valuation approaches. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access Level 2 – Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement.

Acquisition of Atoll GmbH (Tabl

Acquisition of Atoll GmbH (Tables)	6 Months Ended
	Jun. 30, 2016
Consideration Transferred	The total consideration transferred follows (in thousands): Cash consideration, less $74 of working capital adjustments reflected in other receivables as of June 30, 2016 $ 10,176 Value of common stock issued 14,138 Estimated fair value of contingent consideration 952 Total consideration transferred $ 25,266
Components and Allocation of Purchase Price	The components and allocation of the purchase price consists of the following amounts (in thousands): Cash and cash equivalents $ 1,409 Accounts receivable 697 Inventory 155 Other current assets 169 Fixed assets, net 114 Customer relationships 5,318 Developed technology 2,175 Non-competition agreements 57 Trademark and trade name 11 Deferred tax assets 903 Accounts payable and other liabilities assumed (599 ) Deferred tax liabilities (2,245 ) Goodwill 17,102 Net assets acquired $ 25,266

Accumulated Other Comprehensi24

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2016
Summary of Changes in Accumulated Other Comprehensive Income	The following table summarizes the changes in accumulated other comprehensive income by component (in thousands): (In thousands) Unrealized gain Foreign currency Total Balance at December 31, 2015 $ (11 ) $ (8,555 ) $ (8,566 ) Other comprehensive income 15 (633 ) (618 ) Balance at June 30, 2016 $ 4 $ (9,188 ) $ (9,184 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2016
Basic and Diluted Weighted Average Shares Outstanding	Basic and diluted weighted average shares outstanding were as follows: Three months ended Six months ended 2016 2015 2016 2015 Weighted average common shares 33,649,296 32,870,473 33,336,989 32,827,536 Dilutive common stock options 525,831 800,223 525,322 754,146 Weighted average common shares, assuming dilution 34,175,127 33,670,696 33,862,311 33,581,682

Cash, Cash Equivalents and Ma26

Cash, Cash Equivalents and Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2016
Investments in Marketable Securities	Investments in marketable securities consisted of the following at June 30, 2016 (in thousands): June 30, 2016 Amortized Gross Gross Fair Value Marketable securities: U.S. Government and agency securities $ 3,927 $ 2 $ — $ 3,929 Corporate and other debt securities 5,250 2 — 5,252 Total $ 9,177 $ 4 $ — $ 9,181 Investments in marketable securities consisted of the following at December 31, 2015 (in thousands): December 31, 2015 Amortized Gross Gross Fair Value Marketable securities: U.S. Government and agency securities $ 7,029 $ — $ (6 ) $ 7,023 Corporate and other debt securities 10,659 7 (7 ) 10,659 17,688 7 (13 ) 17,682 Long-term marketable securities: U.S. Government and agency securities 838 — (2 ) 836 Corporate and other debt securities 800 — (3 ) 797 1,638 — (5 ) 1,633 Total $ 19,326 $ 7 $ (18 ) $ 19,315

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2016
Schedule of Inventories	Inventories consist of the following (in thousands): June 30, December 31, Raw Materials $ 14,895 $ 10,671 Work-in-process 2,091 1,586 Finished products 6,211 5,741 Total $ 23,197 $ 17,998

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment	Property, plant and equipment consist of the following (in thousands): June 30, 2016 December 31, 2015 Leasehold improvements $ 13,557 $ 13,306 Equipment 14,682 13,758 Furniture and fixtures 3,080 2,808 Construction in progress 621 425 Total property, plant and equipment 31,940 30,297 Less: accumulated depreciation (18,233 ) (16,496 ) Property, plant and equipment, net $ 13,707 $ 13,801

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2016
Intangible assets	Intangible assets consisted of the following at June 30, 2016 (in thousands): Gross Carrying Accumulated Weighted Technology – developed $ 5,413 $ (1,208 ) 13 In process research and development 1,600 — — Patents 240 (192 ) 8 Customer relationships 16,959 (4,385 ) 11 Trademark 700 — — Other intangibles 67 (8 ) 2 Total intangible assets $ 24,979 $ (5,793 ) 12 Intangible assets consisted of the following at December 31, 2015 (in thousands): Gross Carrying Accumulated Weighted Technology – developed $ 3,295 $ (782 ) 12 In process research and development 1,600 — — Patents 240 (177 ) 8 Customer relationships 11,805 (3,926 ) 9 Trademark 700 — — Total intangible assets $ 17,640 $ (4,885 ) 10
Schedule of Amortization Expense for Amortized Intangible Assets	As of June 30, 2016, the Company expects to record amortization expense as follows (in thousands): Years Ending Amortization Expense December 31, 2016 (six months remaining) $ 1,120 December 31, 2017 2,241 December 31, 2018 2,052 December 31, 2019 2,028 December 31, 2020 1,683

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2016
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): June 30, 2016 December 31, 2015 Employee compensation $ 3,800 $ 4,680 Accrued interest payable 251 — Accrued purchases 718 604 Taxes 457 166 Current portion of contingent consideration 5,878 4,480 Professional fees 441 269 Unearned revenue 202 258 Other accrued expenses 1,915 1,600 Total $ 13,662 $ 12,057

Long Term Debt (Tables)

Long Term Debt (Tables)	6 Months Ended
	Jun. 30, 2016
Carrying Value of Convertible Senior Notes	The carrying value of the Company’s convertible senior notes is as follows (in thousands): June 30, 2016 December 31, 2015 2.125% Convertible Senior Notes due 2021: Principal amount $ 115,000 $ — Unamortized debt discount (18,387 ) — Unamortized debt issuance costs (3,233 ) — Total convertible senior notes $ 93,380 $ —

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2016
Stock-Based Compensation Expense	The following table presents stock-based compensation expense included in the Company’s consolidated statements of comprehensive income (in thousands): Three months ended Six months ended 2016 2015 2016 2015 Cost of product revenue $ 84 $ 63 $ 144 $ 106 Research and development 105 90 185 159 Selling, general and administrative 948 832 1,730 1,422 Total $ 1,137 $ 985 $ 2,059 $ 1,687
Summary of Option Activity	Information regarding option activity for the six months ended June 30, 2016 under the Plans is summarized below: Options Weighted- Weighted- (in thousands) Aggregate Options outstanding at January 1, 2016 1,240,935 $ 10.44 Granted 331,203 12.40 Exercised (170,919 ) 5.89 Forfeited/Cancelled (85,480 ) 7.69 Options outstanding at June 30, 2016 1,315,739 $ 11.70 7.33 $ 21,147 Options exercisable at June 30, 2016 514,898 $ 9.49 5.17 $ 9,402 Vested and expected to vest at June 30, 2016 (1) 1,223,223 $ 11.88 7.26 $ 19,473 (1) This represents the number of vested options as of June 30, 2016 plus the number of unvested options expected to vest as of June 30, 2016 based on the unvested outstanding options at June 30, 2016 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2016
Assets Measured at Fair Value on Recurring Basis	The following fair value hierarchy table presents information about each major category of the Company’s assets measured at fair value on a recurring basis as of June 30, 2016 (in thousands): Fair value measurement at reporting date using: Quoted prices in Significant Significant Total Assets: Money market funds $ 131,939 $ — $ — $ 131,939 U.S. Government and agency securities 3,629 300 — 3,929 Corporate and other debt securities — 5,252 — 5,252 Total $ 135,568 $ 5,552 $ — $ 141,120 Liabilities: Contingent consideration – short-term $ — $ — $ 5,878 $ 5,878 Convertible senior notes — 124,295 — 124,295 Total $ — $ 124,295 $ 5,878 $ 130,173
Rollforward of Fair Value of Contingent Consideration	The following table provides a rollforward of the fair value of contingent consideration (in thousands): Balance at December 31, 2015 $ 6,788 Additions 928 Payments (4,480 ) Changes in fair value 2,642 Balance at June 30, 2016 $ 5,878
Refine Technology, LLC
Quantitative Information Associated With Fair Value Measurement of Contingent Consideration	The following tables provide quantitative information associated with the fair value measurement of the Company’s contingent consideration related to Refine using Level 3 inputs (in thousands): Contingent Consideration Refine Fair value as of June 30, 2016 $4,648 Valuation technique Probability-adjusted Remaining period in which milestones can be achieved 2016 Fixed Earn-out Maximum Accrued 2016 4,250 1,300 4,648
Atoll GmbH
Quantitative Information Associated With Fair Value Measurement of Contingent Consideration	The following tables provide quantitative information associated with the fair value measurement of the Company’s contingent consideration related to Atoll using Level 3 inputs (in thousands): Contingent Consideration Atoll Fair value as of June 30, 2016 $928 Valuation technique Probability-weighted Remaining period in which milestones can be achieved 2016

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2016
Future Minimum Rental Commitments under Company's Leases	Future minimum rental commitments under the Company’s leases as of June 30, 2016 are as follows (in thousands): Minimum Rental 2016 $ 2,031 2017 1,434 2018 1,434 2019 1,387 2020 1,371 Thereafter 2,700

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2016
Percentage of Revenue from Significant Customers	Revenue from significant customers as a percentage of the Company’s total revenue is as follows: Three months ended Six months ended 2016 2015 2016 2015 GE Healthcare 28 % 51 % 31 % 44 % MilliporeSigma 30 % 25 % 30 % 31 %
Total Revenue
Percentage by Geographic Area or Significant Customers	The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three months ended Six months ended 2016 2015 2016 2015 United States 45 % 21 % 37 % 25 % Sweden 29 % 51 % 31 % 44 % United Kingdom 6 % 17 % 10 % 18 % Other 20 % 11 % 22 % 13 % Total 100 % 100 % 100 % 100 %
Accounts Receivable
Percentage by Geographic Area or Significant Customers	Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable are as follows: June 30, December 31, GE Healthcare 49 % 13 % MilliporeSigma 13 % 32 % Bioprocessing Customer C 3 % 21 %

Acquisition of Atoll GmbH (Deta

Acquisition of Atoll GmbH (Detail)	Apr. 01, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / shares	Dec. 31, 2015$ / shares	Jun. 30, 2016EUR (€)	Apr. 01, 2016EUR (€)
Business Acquisition [Line Items]
Common stock, par value | $ / shares		$ 0.01	$ 0.01
Finite lived intangible asset, useful life		12 years	10 years
Customer relationships
Business Acquisition [Line Items]
Finite lived intangible asset, useful life		11 years	9 years
Technology - developed
Business Acquisition [Line Items]
Finite lived intangible asset, useful life		13 years	12 years
Atoll GmbH
Business Acquisition [Line Items]
Stock consideration | shares	538,700
Common stock, par value | $ / shares	$ 0.01
Value of common stock issued	$ 14,138,000
Business combination, consideration transferred	25,266,000
Cash consideration	10,176,000
Working capital adjustments	74,000
Earnout consideration	1,100,000
Estimated fair value of contingent consideration	952,000	$ 928,000		€ 836,000
Fair value of net assets acquired	25,266,000
Business acquisition, transaction costs	1,119,000
Fair value of acquired finite lived intangible assets | €					€ 6,640,000
Atoll GmbH | Customer relationships
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	$ 5,318,000
Finite lived intangible asset, useful life	16 years
Atoll GmbH | Technology - developed
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	$ 2,175,000
Finite lived intangible asset, useful life	14 years
Atoll GmbH | Non-competition agreements
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	$ 57,000
Finite lived intangible asset, useful life	2 years
Atoll GmbH | Trademark/ tradename
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	$ 11,000
Finite lived intangible asset, useful life	2 years
Atoll GmbH | Up Front Payment
Business Acquisition [Line Items]
Cash consideration	$ 10,200,000

Consideration Transferred (Deta

Consideration Transferred (Detail) - Atoll GmbH € in Thousands, $ in Thousands	Apr. 01, 2016USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2016EUR (€)
Business Acquisition [Line Items]
Cash consideration, less $74 of working capital adjustments reflected in other receivables as of June 30, 2016	$ 10,176
Value of common stock issued	14,138
Estimated fair value of contingent consideration	952	$ 928	€ 836
Total consideration transferred	$ 25,266

Consideration Transferred (Pare

Consideration Transferred (Parenthetical) (Detail) $ in Thousands	Apr. 01, 2016USD ($)
Atoll GmbH
Business Acquisition [Line Items]
Working capital adjustments reflected in other receivables as of June 30, 2016	$ 74

Components and Allocation of Pu

Components and Allocation of Purchase Price (Detail) $ in Thousands	Jun. 30, 2016USD ($)	Apr. 01, 2016USD ($)	Apr. 01, 2016EUR (€)	Dec. 31, 2015USD ($)
Business Acquisition [Line Items]
Goodwill	$ 31,026			$ 14,346
Atoll GmbH
Business Acquisition [Line Items]
Cash and cash equivalents		$ 1,409
Accounts receivable		697
Inventory		155
Other current assets		169
Fixed assets, net		114
Business combination, intangible assets | €			€ 6,640,000
Deferred tax assets		903
Accounts payable and other liabilities assumed		(599)
Deferred tax liabilities		(2,245)
Goodwill		17,102
Net assets acquired		25,266
Atoll GmbH | Customer relationships
Business Acquisition [Line Items]
Business combination, intangible assets		5,318
Atoll GmbH | Technology - developed
Business Acquisition [Line Items]
Business combination, intangible assets		2,175
Atoll GmbH | Non-competition agreements
Business Acquisition [Line Items]
Business combination, intangible assets		57
Atoll GmbH | Trademark/ tradename
Business Acquisition [Line Items]
Business combination, intangible assets		$ 11

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($)	Sep. 03, 2014	Jan. 30, 2014	Mar. 31, 2014	Jun. 30, 2016
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Non-refundable up-front payment				$ 2,000,000
Payment to be received upon signing of agreement				125,675
Revenue recognized				2,115,000
Revenue recognized under revenue recognition, up front payment			$ 2,000,000
Clinical Development
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Milestone Payment				60,000,000
Potential milestone payments to be received				60,000,000
Initial Commercial Sales
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Potential milestone payments to be received				100,000,000
BioMarin Pharmaceutical, Inc. | Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Upfront payment received under purchase agreement		$ 2,000,000
Potential milestone payments to be received				160,000,000
Provision for refund				$ 0
BioMarin Pharmaceutical, Inc. | Clinical Development | Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Percentage relate to clinical development from Milestone payment				37.00%
BioMarin Pharmaceutical, Inc. | Initial Commercial Sales | Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Percentage relate to clinical development from Milestone payment				63.00%
BioMarin Pharmaceutical, Inc. | Technology Transfer Payments | Asset Purchase Agreement
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Milestone Payment	$ 125,675

Change in Accumulated Other Com

Change in Accumulated Other Comprehensive Income (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at December 31, 2015	$ 122,748
Other comprehensive income	(618)
Balance at June 30, 2016	163,724
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at December 31, 2015	(8,566)
Balance at June 30, 2016	(9,184)
Accumulated Net Unrealized Investment Gain (Loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at December 31, 2015	(11)
Other comprehensive income	15
Balance at June 30, 2016	4
Accumulated Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at December 31, 2015	(8,555)
Other comprehensive income	(633)
Balance at June 30, 2016	$ (9,188)

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Earnings Per Share [Line Items]
Participating securities outstanding	0	0
Stock options, outstanding	1,315,739	1,265,486	1,315,739	1,265,486	1,240,935
Stock options, weighted average exercise price	$ 11.70	$ 9.68	$ 11.70	$ 9.68	$ 10.44
Common stock excluded from calculation of diluted earnings per share	359,828	126,541	417,279	150,041

Basic and Diluted Weighted Aver

Basic and Diluted Weighted Average Shares Outstanding (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Weighted Average Number of Shares Outstanding [Line Items]
Weighted average common shares	33,649,296	32,870,473	33,336,989	32,827,536
Dilutive common stock options	525,831	800,223	525,322	754,146
Weighted average common shares, assuming dilution	34,175,127	33,670,696	33,862,311	33,581,682

Cash, Cash Equivalents and Ma44

Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2016USD ($)Investment	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)
Cash, cash equivalents and marketable securities [Line Items]
Long-term marketable securities, minimum original maturity term	1 year
Marketable securities, average remaining contractual maturity period	3 months 16 days
Long-term marketable securities	$ 0		$ 1,633,000
Number of debt securities in unrealized loss positions | Investment	3
Debt securities in unrealized loss positions, total fair market value	$ 1,302,000
Credit risk	0
Gain (loss) on investments	$ 0	$ 0
Minimum
Cash, cash equivalents and marketable securities [Line Items]
Short-term marketable securities, minimum original maturity term	90 days
Maximum
Cash, cash equivalents and marketable securities [Line Items]
Debt securities in unrealized loss positions, total unrealized loss	$ 1,000

Investments in Marketable Secur

Investments in Marketable Securities (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 19,326
Gross Unrealized Gain		7
Gross Unrealized Loss		(18)
Fair Value		19,315
Marketable securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 9,177	17,688
Gross Unrealized Gain	4	7
Gross Unrealized Loss		(13)
Fair Value	9,181	17,682
Marketable securities | U.S. Government and agency securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	3,927	7,029
Gross Unrealized Gain	2
Gross Unrealized Loss		(6)
Fair Value	3,929	7,023
Marketable securities | Corporate and other debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	5,250	10,659
Gross Unrealized Gain	2	7
Gross Unrealized Loss		(7)
Fair Value	$ 5,252	10,659
Long-term marketable securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		1,638
Gross Unrealized Loss		(5)
Fair Value		1,633
Long-term marketable securities | U.S. Government and agency securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		838
Gross Unrealized Loss		(2)
Fair Value		836
Long-term marketable securities | Corporate and other debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		800
Gross Unrealized Loss		(3)
Fair Value		$ 797

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Reserves for excess and obsolete inventory	$ 343,000	$ 343,000

Schedule of Inventories (Detail

Schedule of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Raw materials	$ 14,895	$ 10,671
Work-in-process	2,091	1,586
Finished products	6,211	5,741
Total	$ 23,197	$ 17,998

Property, Plant and Equipment48

Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Leasehold improvements	$ 13,557	$ 13,306
Equipment	14,682	13,758
Furniture and fixtures	3,080	2,808
Construction in progress	621	425
Total property, plant and equipment	31,940	30,297
Less: accumulated depreciation	(18,233)	(16,496)
Property, plant and equipment, net	$ 13,707	$ 13,801

Property, Plant and Equipment -

Property, Plant and Equipment - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Depreciation expense of property and equipment	$ 1,535,000	$ 1,494,000

Other Intangible Assets (Detail

Other Intangible Assets (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Intangible Assets [Line Items]
Gross Carrying Amount	$ 24,979	$ 17,640
Accumulated Amortization	$ (5,793)	$ (4,885)
Weighted Average Useful Life (in years)	12 years	10 years
Technology - developed
Intangible Assets [Line Items]
Gross Carrying Amount	$ 5,413	$ 3,295
Accumulated Amortization	$ (1,208)	$ (782)
Weighted Average Useful Life (in years)	13 years	12 years
Patents
Intangible Assets [Line Items]
Gross Carrying Amount	$ 240	$ 240
Accumulated Amortization	$ (192)	$ (177)
Weighted Average Useful Life (in years)	8 years	8 years
Customer relationships
Intangible Assets [Line Items]
Gross Carrying Amount	$ 16,959	$ 11,805
Accumulated Amortization	$ (4,385)	$ (3,926)
Weighted Average Useful Life (in years)	11 years	9 years
Other intangibles
Intangible Assets [Line Items]
Gross Carrying Amount	$ 67
Accumulated Amortization	$ (8)
Weighted Average Useful Life (in years)	2 years
In process research and development ("IPR&D")
Intangible Assets [Line Items]
Gross Carrying Amount, indefinite lived intangible assets	$ 1,600	$ 1,600
Trademark
Intangible Assets [Line Items]
Gross Carrying Amount, indefinite lived intangible assets	$ 700	$ 700

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 932,000	$ 801,000

Amortization Expense for Amorti

Amortization Expense for Amortized Intangible Assets (Detail) $ in Thousands	Jun. 30, 2016USD ($)
Finite-Lived Intangible Assets [Line Items]
December 31, 2016 (six months remaining)	$ 1,120
December 31, 2017	2,241
December 31, 2018	2,052
December 31, 2019	2,028
December 31, 2020	$ 1,683

Schedule of Accrued Liabilities

Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Schedule of Accrued Liabilities [Line Items]
Employee compensation	$ 3,800	$ 4,680
Accrued interest payable	251
Accrued purchases	718	604
Taxes	457	166
Current portion of contingent consideration	5,878	4,480
Professional fees	441	269
Unearned revenue	202	258
Other accrued expenses	1,915	1,600
Total	$ 13,662	$ 12,057

Carrying Value of Convertible S

Carrying Value of Convertible Senior Notes (Detail) - 2.125% Convertible Senior Notes due 2021 $ in Thousands	Jun. 30, 2016USD ($)
Debt Instrument [Line Items]
Principal amount	$ 115,000
Unamortized debt discount	(18,387)
Unamortized debt issuance costs	(3,233)
Total convertible senior notes	$ 93,380

Carrying Value of Convertible55

Carrying Value of Convertible Senior Notes (Parenthetical) (Detail) - 2.125% Convertible Senior Notes due 2021	6 Months Ended
	Jun. 30, 2016	May 24, 2016
Debt Instrument [Line Items]
Notes, interest rate	2.125%	2.125%
Notes, due date	Jun. 1, 2021

Long Term Debt - Additional Inf

Long Term Debt - Additional Information (Detail)	May 24, 2016USD ($)d$ / shares	Jun. 30, 2016USD ($)	Jun. 30, 2016USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of convertible senior notes, net of costs			$ 111,323,000
Accretion of the debt discount			$ 382,000
2.125% Convertible Senior Notes due 2021
Debt Instrument [Line Items]
Notes issued	$ 115,000,000
Notes, interest rate	2.125%	2.125%	2.125%
Notes, frequency of periodic payment			Semi-annually
Notes, date of first required payment			Dec. 1, 2016
Notes, due date			Jun. 1, 2021
Notes conversion ratio per $1,000 principal amount	0.0311813
Notes initial conversion price | $ / shares	$ 32.07
Debt covenants debt default holder percent to declare all notes due minimum	25.00%
Number of days within which entity fails to satisfy obligations considered as event of default	270 days
Notes issued, fair value	$ 96,289,000
Contractual coupon interest		$ 251,000
Accretion of the debt discount		324,000
Amortization of the debt issuance costs		$ 57,000
Effective interest rate on the Notes		6.60%	6.60%
Notes, carrying value		$ 93,380,000	$ 93,380,000
Fair value of the note		$ 124,300,000	$ 124,300,000
2.125% Convertible Senior Notes due 2021 | On any business day on or after June 5, 2019 and prior to the maturity date
Debt Instrument [Line Items]
Notes threshold percentage of stock price trigger	130.00%
Notes threshold trading days | d	20
Notes threshold consecutive trading days	30 days
Notes redemption price	100.00%

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,137,000	$ 985,000	$ 2,059,000	$ 1,687,000
Stock options, outstanding	1,315,739	1,265,486	1,315,739	1,265,486	1,240,935
Number of shares available for future grant	1,976,534		1,976,534
Closing price of common stock	$ 27.36		$ 27.36
Weighted average grant date fair value of share-based awards granted			$ 20.11	$ 21.83
Total fair value of stock options vested			$ 2,396,000	$ 1,522,000
Total unrecognized compensation cost	$ 9,613,000		$ 9,613,000
Unrecognized compensation cost, weighted average remaining requisite service period			2 years 10 months 28 days
Number of unvested options	708,325		708,325
Unvested Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period			5 years
Employee Stock Option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period			3 years
Employee Stock Option | Minimum | Vest Over Three Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting percentage			20.00%
Employee Stock Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period			5 years
Incentive options, term			10 years
Employee Stock Option | Maximum | Vest Over Five Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting percentage			33.00%
Non-Employee Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period			1 year

Stock-Based Compensation Expens

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,137	$ 985	$ 2,059	$ 1,687
Cost of product revenue
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	84	63	144	106
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	105	90	185	159
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 948	$ 832	$ 1,730	$ 1,422

Summary of Information Regardin

Summary of Information Regarding Option Activity (Detail) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)$ / sharesshares
Options Outstanding
Options outstanding at January 1, 2016 | shares	1,240,935
Granted | shares	331,203
Exercised | shares	(170,919)
Forfeited/Cancelled | shares	(85,480)
Options outstanding at June 30, 2016 | shares	1,315,739
Options exercisable at June 30, 2016 | shares	514,898
Vested and expected to vest at June 30, 2016 | shares	1,223,223	[1]
Weighted-Average Exercise Price Per Share
Options outstanding at January 1, 2016 | $ / shares	$ 10.44
Granted | $ / shares	12.40
Exercised | $ / shares	5.89
Forfeited/Cancelled | $ / shares	7.69
Options outstanding at June 30, 2016 | $ / shares	11.70
Options exercisable at June 30, 2016 | $ / shares	9.49
Vested and expected to vest at June 30, 2016 | $ / shares	$ 11.88	[1]
Weighted-Average Remaining Contractual Term (in years)
Options outstanding at June 30, 2016	7 years 3 months 29 days
Options exercisable at June 30, 2016	5 years 2 months 1 day
Vested and expected to vest at June 30, 2016	7 years 3 months 4 days	[1]
Aggregate Intrinsic Value
Options outstanding at June 30, 2016 | $	$ 21,147
Options exercisable at June 30, 2016 | $	9,402
Vested and expected to vest at June 30, 2016 | $	$ 19,473	[1]
[1]	This represents the number of vested options as of June 30, 2016 plus the number of unvested options expected to vest as of June 30, 2016 based on the unvested outstanding options at June 30, 2016 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.

Summary of Information Regard60

Summary of Information Regarding Option Activity (Parenthetical) (Detail) - Employee Stock Option	Jun. 30, 2016
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8.00%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015	Jun. 30, 2016USD ($)	Jun. 30, 2015	Apr. 01, 2016EUR (€)	Dec. 31, 2015USD ($)
Income Taxes [Line Items]
Effective tax rate	27.90%	17.00%	30.50%	23.50%
U.S. statutory tax rate	34.00%	34.00%	34.00%	34.00%
Atoll GmbH
Income Taxes [Line Items]
Business combination, intangible assets | €					€ 6,640,000
Deferred tax liabilities, intangible assets	$ 2,190,000		$ 2,190,000		1,972,000
Deferred tax assets, net operating losses | €					2,669,000
Deferred tax assets, intangible assets	$ 880,000		$ 880,000		€ 793,000
Latest Tax Year
Income Taxes [Line Items]
Net operating loss and business tax credit carry forwards expiration date			At various dates through December 2035.
Available to Reduce Future Federal Income Taxes
Income Taxes [Line Items]
Net operating loss carry forwards | $						$ 46,984,000
Business tax credit carry forwards | $						$ 1,920,000

Major Category of Assets Measur

Major Category of Assets Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring $ in Thousands	Jun. 30, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	$ 141,120
Liabilities	130,173
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	131,939
U.S. Government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	3,929
Corporate and other debt securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	5,252
Contingent consideration - short-term
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities	5,878
Convertible Senior Note
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities	124,295
Quoted prices in active markets for identical assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	135,568
Quoted prices in active markets for identical assets (Level 1) | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	131,939
Quoted prices in active markets for identical assets (Level 1) | U.S. Government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	3,629
Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	5,552
Liabilities	124,295
Significant other observable inputs (Level 2) | U.S. Government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	300
Significant other observable inputs (Level 2) | Corporate and other debt securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets	5,252
Significant other observable inputs (Level 2) | Convertible Senior Note
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities	124,295
Significant unobservable inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities	5,878
Significant unobservable inputs (Level 3) | Contingent consideration - short-term
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities	$ 5,878

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016EUR (€)	May 24, 2016USD ($)	Apr. 01, 2016USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of other assets	$ 0		$ 0
Fair value of other liabilities	0		0
Increase to milestone payment	$ 637,000	$ 768,000	2,642,000	$ 1,881,000
Payment of contingent considerations			$ 498,000	$ 99,000
2.125% Convertible Senior Notes due 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Principal amount						$ 115,000,000
Notes, interest rate	2.125%		2.125%		2.125%	2.125%
Notes, due date			Jun. 1, 2021
Notes, frequency of periodic payment			Semi-annually
Notes, date of first required payment			Dec. 1, 2016
Total convertible senior notes	$ 93,380,000		$ 93,380,000
Fair value of convertible senior notes	124,300,000		124,300,000
Refine Technology, LLC
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Increase to milestone payment			2,629,000
Refine Technology, LLC | Milestone Payments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Payment of contingent considerations			4,350,000
Bio Flash | Minimum
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Royalty payment			130,000
Atoll GmbH
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Accrued Balance	928,000		928,000		€ 836		$ 952,000
Significant unobservable inputs (Level 3) | Refine Technology, LLC | Milestone Payments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Increase to milestone payment			2,629,000
Accrued Balance	4,648,000		4,648,000
Significant unobservable inputs (Level 3) | Atoll GmbH | Milestone Payments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Accrued Balance	$ 928,000		$ 928,000		€ 836

Rollforward of Fair Value of Co

Rollforward of Fair Value of Contingent Consideration (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2015	$ 6,788
Additions	928
Payments	(4,480)
Changes in fair value	2,642
Balance at June 30, 2016	$ 5,878

Quantitative Information Associ

Quantitative Information Associated With Fair Value Measurement of Contingent Consideration (Detail) € in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2016EUR (€)	Apr. 01, 2016USD ($)
Atoll GmbH
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Accrued Balance	$ 928,000	€ 836	$ 952,000
Significant unobservable inputs (Level 3) | Refine Technology, LLC | Milestone Payments
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Accrued Balance	$ 4,648,000
Valuation technique	Probability-adjusted discounted cash flow
Remaining period in which milestones can be achieved	2,016
Significant unobservable inputs (Level 3) | Refine Technology, LLC | Milestone Payments | Scenario, Actual
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fixed Earn-out	$ 4,250,000
Maximum Variable Earn-out	1,300,000
Accrued Balance	4,648,000
Significant unobservable inputs (Level 3) | Atoll GmbH | Milestone Payments
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Accrued Balance	$ 928,000	€ 836
Valuation technique	Probability-weighted expected return method.
Remaining period in which milestones can be achieved	2,016

Future Minimum Rental Commitmen

Future Minimum Rental Commitments under Company's Leases (Detail) $ in Thousands	Jun. 30, 2016USD ($)
Operating Leased Assets [Line Items]
2,016	$ 2,031
2,017	1,434
2,018	1,434
2,019	1,387
2,020	1,371
Thereafter	$ 2,700

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2016Segment
Segment Reporting Information [Line Items]
Number of operating segment	1

Percentage of Revenue by Geogra

Percentage of Revenue by Geographic Area (Detail) - Geographic Concentration Risk - Total Revenue	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Concentration Risk [Line Items]
Revenues, percentage by country	100.00%	100.00%	100.00%	100.00%
United States
Concentration Risk [Line Items]
Revenues, percentage by country	45.00%	21.00%	37.00%	25.00%
Sweden
Concentration Risk [Line Items]
Revenues, percentage by country	29.00%	51.00%	31.00%	44.00%
United Kingdom
Concentration Risk [Line Items]
Revenues, percentage by country	6.00%	17.00%	10.00%	18.00%
Other
Concentration Risk [Line Items]
Revenues, percentage by country	20.00%	11.00%	22.00%	13.00%

Percentage of Revenue from Sign

Percentage of Revenue from Significant Customers (Detail) - Customer Concentration Risk - Sales Revenue	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
GE Healthcare
Revenue, Major Customer [Line Items]
Revenue from significant customers as a percentage of total revenue	28.00%	51.00%	31.00%	44.00%
MilliporeSigma
Revenue, Major Customer [Line Items]
Revenue from significant customers as a percentage of total revenue	30.00%	25.00%	30.00%	31.00%

Percentage of Accounts Receivab

Percentage of Accounts Receivable by Significant Customers (Detail) - Customer Concentration Risk - Accounts Receivable	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
GE Healthcare
Concentration Risk [Line Items]
Accounts receivable, percentage by customer	49.00%	13.00%
MilliporeSigma
Concentration Risk [Line Items]
Accounts receivable, percentage by customer	13.00%	32.00%
Bioprocessing Customer C
Concentration Risk [Line Items]
Accounts receivable, percentage by customer	3.00%	21.00%